When AstraZeneca chief Pascal Soriot said the drugmaker would make $80bn in revenue by 2030, his goal seemed wildly ambitious ...

AstraZeneca’s former head of its China business has been formally charged by the country’s authorities with illegal trading, ...

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into ...

CEO Pascal Soriot said in a call with reporters on Tuesday that the group’s confidence in reaching $80 billion in revenue in ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.

Former AstraZeneca regional head Leon Wang was detained by Chinese authorities more than a year ago in connection with probes ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

Feb 11 (Reuters) - China has officially charged AstraZeneca's former head of the business in the country, Leon Wang, who had been in detention since October 2024, the drugmaker confirmed to Reuters on ...

Feb 11 (Reuters) - China has officially charged AstraZeneca's former regional head, Leon Wang, who was detained by ...